ABSTRACT
Objective Setting up a method to detect YMDD mutation during lamivudine therapy. Methods Two specific fluorescent probes were designed, on the unpaired base can remarkably affect melting temperature when oligonucleotide probe binding to DNA template. 297 patients (354 sera samples) were detected YMDD mutation by real time fluorimetry PCR. Results 156 YMDD mutation were found in 354 sera samples (44.1%), in which the mixed variant species were 34%(53/156). In the same time, nine sera samples wre sequenced. The results of sequencing were fully corresponded to those of fluorimetry PCR. The statistical analysis showed that YMDD variants were obviously correlated with ALT level(P
ABSTRACT
Objective To explore pre C and YMDD motif mutant of hepatitis B virus during lamivudine therapy. Methods From five chronic hepatitis B patients with serum HBeAg seroconversion but HBV DNA positive by polymerase chain reaction(PCR) following lamivudine therapy, sequences of the pre C and P genes of hepatitis B virus were analyzed by direct PCR product sequencing methods. Results All the five patients were observed to have G to A variations at nucleotide 1896. However, such mutations were observed only in 2 of the 5 patients before HBeAg seroconversion emerged. Meanwhile YMDD mutations were found in all the five patients during lamivudine therapy three of which were M552I mutants, two were M552I associated with L528M. One of the five patients had no reaction to the therapy, four had HBV DNA breakthrough during therapy. Conclusions The mutants of pre C associated with YMDD mutations may arise in the patients with HBeAg seroconversion and positive HBV DNA during the treatment of lamivudine. HBV DNA should be detected in the patients with HBeAg seroconversion to exclude the pre C mutation.
ABSTRACT
Objective To investigate the efficacy, tolerability and safety profiles of PEG IFN alpha 2a(PEG IFN? 2a) in the treatment of chronic hepatitis C in China. Methods 208 patients with chronic hepatitis C were included, and divided into two groups randomly, PEG IFN? 2a group and IFN? 2a Group respectively. There was no significant difference between two groups in pretreatment HCV RNA, HCV genotype and other clinical data. The main parameters to valuate the efficacy were virological response and biochemical response. The side effects were intensively observed. Results Sustained virological response rate in PEG IFN? 2a group was significantly higher than that in IFN? 2a group (41.51% and 16.67% respectively, P